Intra-Cellular Therapies retained earnings (accumulated deficit) for the quarter ending December 31, 2024 were $-1.692B, a 4.62% increase year-over-year.
Intra-Cellular Therapies retained earnings (accumulated deficit) for 2024 were $-1.692B, a 4.62% increase from 2023.
Intra-Cellular Therapies retained earnings (accumulated deficit) for 2023 were $-1.617B, a 9.45% increase from 2022.
Intra-Cellular Therapies retained earnings (accumulated deficit) for 2022 were $-1.477B, a 20.98% increase from 2021.